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Abstract
Background: Previous studies have suggested that patients with peripheral artery disease (PAD) suffer from a high
incidence of cardiovascular events (CVE). Visceral adiposity has been implicated in promoting CVEs. This study aimed to
assess the association of relative visceral adipose volume with incident cardiovascular events in patients with peripheral
artery disease.
Methods: This was a prospective cohort study including 260 patients with PAD who presented between 2003 and 2012.
Cases were patients with diagnosed PAD including symptomatic lower limb athero-thrombosis and asymptomatic
abdominal aortic aneurysm. All patients underwent computed tomography angiography (CTA). Abdominal visceral to total
adipose volume ratio (relative visceral adipose volume) was estimated from CTAs using a previously validated workstation
protocol. Cardiovascular risk factors were recorded at entry. The association of visceral adiposity with major CVEs (death,
non-fatal myocardial infarction or stroke) was examined using Kaplan Meier and Cox proportional hazard analyses.
Results: A total of 92 major CVEs were recorded in 76 patients during a median follow-up of 2.8 (IQR 1.2 to 4.8) years,
including myocardial infarction (n = 26), stroke (n = 10) and death (n = 56). At 3 years the incidence of major CVEs stratified
by relative visceral adipose volume quartiles were 15% [Quartile (Q) 1], 17% (Q2), 11% (Q3) and 15% (Q4) (P= 0.517). Relative
visceral adipose volume was not associated with major CVEs after adjustment for other risk factors.
Conclusion: This study suggests that visceral adiposity does not play a central role in the predisposition for major CVEs in
patients with PAD.
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Introduction
Patients with peripheral artery disease (PAD) [i.e. stenosing or
aneurysmal disease outside the coronary circulation] have a high
incidence of cardiovascular events (CVEs) [1–4]. The incidence of
major CVEs in patients with PAD has been reported in some
studies to be higher than in patients with athero-thrombosis
affecting other vascular sites, such as coronary heart disease
[5],[6].
Current management of CVE risk reduction in PAD patients is
limited with a number of previous studies reporting that patients
with PAD are frequently managed less intensively than patients
with athero-thrombosis at other sites despite a high incidence of
major CVEs [7–9]. There is considerable interest in identifying
modifiable risk factors that could decrease the high incidence of
CVEs seen in patients with PAD [1]. Obesity is an established risk
factor for cardiovascular disease and CVEs in patients with
coronary heart disease [10], [11]. A recent systematic review
suggested that obesity was associated with cardiovascular events in
patients with PAD [12]. Adipose is deposited at both subcutaneous
and visceral sites [13]. It has been suggested that visceral adipose
may have a unique composition of white relative to brown adipose
that has been implicated in the secretion of pro-inflammatory
cytokines which could promote CVEs [14]. Reduction of visceral
adipose could provide a new avenue for risk reduction [2]. For
example previous studies have reported that visceral adipose can
be targeted by exercise regimens and thus visceral adiposity is
potentially a modifiable risk factor [15], [16].
Markers of visceral adiposity, such as waist circumference (WC)
and waist to hip ratio (WHR) have been independently associated
with the severity and prognosis of lower limb atherosclerosis [2],
[17]. The measures of visceral adiposity previously used do not
however directly assess the amount of visceral adipose tissue. We
have previously designed and validated a method to measure
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visceral adipose volume from thresholded computed tomographic
angiography (CTA) images [18]. The association of visceral
adipose volume with incident CVEs in patients with PAD has not
been previously assessed. The aim of this study was to assess the
association between visceral adipose volume and incident major
CVEs in patients with PAD.
Methodology
Study Participants and Definitions
This research was approved by the Townsville Health Service
District Human Research Ethics Committee. This was a
prospective cohort study of patients who presented to The
Townsville Hospital vascular clinic between May 2003 and
February 2012. Patients presented to clinic for investigation or
surveillance of PAD. Patients were assessed by a vascular surgeon
that diagnosed PAD based on appropriate symptoms and signs of
lower limb athero-thrombosis and CTA imaging evidence of lower
limb atherosclerosis or abdominal aortic aneurysm (AAA). AAA
was defined as an infra-renal aortic diameter $30 mm. All
included patients were diagnosed with lower-limb athero-throm-
bosis, AAA or both. Inclusion criteria were as follows: 1) Verbal
and written consent; and 2) a clinical need for CTA. Exclusion
criteria were: 1) Urgent requirement for peripheral vascular
surgical intervention; 2) contra-indication to CTA. There were no
further inclusion or exclusion criteria.
Computed tomography angiography analysis
All CTAs were performed at The Townsville Hospital using a
64-slice multi-scanner (Philips, North Ryde, NSW) under a set
protocol. Images were recorded at 3 mm intervals with a slice
thickness of 3 mm enabling the construction of 3 mm adjoining
axial images for analysis. One hundred millimetres of Ultravist 300
contrast agent was administered intra-venously by an automatic
CTA injection driver system (MEDRAD). The CTA imaging
commenced once the Hounsfield Unit (HU) at the centre of the
aorta reached 130. CTA imaging was transferred to Philips
MxView Visualisation Workstation software for analysis. The two
researchers performing measurements underwent a comprehen-
sive training program provided by a clinician experienced in use of
the workstation.
Assessment of abdominal adipose volume
A protocol was designed which combined techniques described
in published literature with approaches learnt whilst performing
aortic volumetric analysis [19–23]. This protocol has been
previously described [18]. Briefly, the radiographic threshold
was set to the pre-defined threshold for adiposity (CH 2120 HU,
WH 75 HU). The axial slice at which the superior aspect of the
first sacral body appeared was identified. The ‘‘Volume of
Interest’’ tool was used to manually circumscribe the entire torso
at this slice. The axial slice 125 mm cephalad to the first slice was
identified and circumscribed with the ‘‘Volume of Interest’’ tool.
In a semi-automated system, the axial slices between these points
were methodically joined to form a deposit of adipose tissue.
‘‘Tissue Volume’’ was selected to provide the total adipose tissue
volume.
In a similar process the visceral adipose volume was calculated
from axial CTA images. Firstly the visceral compartment at the
most superior aspect of the first sacral body was manually traced
using the ‘‘Volume of Interest’’ tool. Secondly the visceral
compartment on the axial slice 125 mm cephalad was circum-
scribed. The axial slices between these points were joined in a
semi-automated fashion to create an estimation of the visceral
adipose volume. Subcutaneous adipose volume was calculated
from the difference between total and visceral adipose volumes.
Measurements were displayed to the nearest 0.01 cm3 [18].
Reproducibility analysis for adipose volume
A reproducibility analysis of the first 15 participants recruited
into the study was completed by two observers as previously
reported [18]. Intra-observer reproducibility measurements were
completed three times with at least one week in between
measurement sets. Inter-observer reproducibility was completed
at least one week after the intra-observer measurements were
complete. Data was analysed by a third independent observer.
The intra- and inter-observer concordance correlation coefficients
(CCC) for total adipose volume measurements were 1.0 (95% CI,
1.0 to 1.0) and 1.0 (95% CI, 1.0 to 1.0) respectively. The intra- and
inter-observer average coefficients of variation (ACV) for total
adipose volume were 0.8% and 1.2% respectively. The CCCs for
intra- and inter-observer visceral adipose volumes were 1.0 (1.0 to
1.0) and 1.0 (1.0 to 1.0) respectively. The ACV for intra- and inter-
observer visceral adipose volume were 1.9% and 3.4% respec-
tively.
Clinical data
Baseline characteristics collected for each patient at entry to the
study included: Gender; age; hypertension; diabetes; coronary
heart disease and medication prescription. Diabetes and hyper-
tension were defined by history of diagnosis or treatment of these
conditions. History of smoking was defined as ever or never
smoked. Coronary heart disease was defined by a history of
angina, myocardial infarction or coronary revascularisation.
Current medication history was recorded with respect to
prescription of angiotensin converting enzyme (ACE) inhibitors,
angiotensin receptor blockers, aspirin, beta-blockers, calcium
channel blockers, other anti-platelet medication, statins and
warfarin.
Follow-up for cardiovascular events
After the initial assessment and imaging the frequency of patient
review was dependent on the patient’s presenting complaint.
Patients with intermittent claudication were typically reviewed six
months after entry to the study and annually thereafter. Patients
with small AAAs (i.e. 30–39 mm) were typically reviewed annually
and patients with larger AAAs (i.e. $40 mm) were typically
reviewed bi-annually.
The primary outcome measure in this study was the incidence
of major CVEs including non-fatal myocardial infarction, non-
fatal stroke or death. Secondary outcome measures were non-fatal
myocardial infarction and non-fatal stroke. Outcome data was
recorded either at clinic appointments or during hospital
admissions. Cause of death was verified by the death certificate
where possible. Patient charts were reviewed to ensure hospital
admissions were not missed.
Statistical analysis
Based on previous studies we estimated over an average follow-
up of approximately three years that the incidence of death,
myocardial infarction or stroke would be 30% [2], [24]. We
planned to perform a Cox proportional analysis to assess the
association of visceral adiposity with cardiovascular events
adjusted for the following risk factors: Age, gender, coronary
heart disease, diabetes, hypertension and smoking. Thus we
estimated that we needed to include approximately 230 patients in
order to achieve 10 outcome events per risk factor included in the
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planned Cox regression model. Previous studies suggest this
approach provides sufficient power to assess this number of
dependent variables [25]. Data were prospectively recorded in an
Access database and subsequently transferred to a Microsoft Excel
spread sheet and then to SPSS Version 20.0 (IBM SPSS Inc.,
Chicago, Illinois) for statistical analysis. Abdominal visceral to total
adipose volume ratio (relative visceral adipose volume) was
calculated for all cases. Participants were stratified into quartiles
[Quartiles (Q) 1 to 4] determined by their relative visceral
adipose volume in ascending order for analysis. Histograms and
Kolmogorov-Smirnov tests demonstrated that numerical data
were not normally distributed. Statistical methods of survival
analysis were applied to assess occurrence of CVE during follow-
up. Follow-up time was defined as the time between the date of the
initial CTA and occurrence of the first CVE or last observation.
Kaplan Meier analysis was used to estimate cumulative survival
probability for CVE incidence. The independent association of
visceral adiposity with the incidence of CVEs was assessed by Cox
proportional hazard analysis adjusting for established risk
factors, including age, coronary heart disease, diabetes, gender,
Table 1. Association of entry cardiovascular risk factors with visceral adiposity at the time of CTA imaging.
Relative visceral adipose volume
Characteristic Quartile 1 (n =65) Quartile 2 (n =65) Quartile 3 (n=65) Quartile 4 (n =65) P value
Age (years) 70 (62–76) 68 (61–75) 72 (65–76) 70 (64–76) 0.188
Body Mass Index (kg/m2) 26.8 (23.7–29.9) 28.7 (24.2–31.1) 28.7 (25.1–31.4) 28.4 (26.1–31.7) 0.240
Coronary Heart Disease 28 (43) 38 (58) 31 (48) 38 (58) 0.193
Diabetes mellitus 15 (23) 18 (28) 21 (32) 30 (46) 0.031
Ever smoked 55 (85) 54 (83) 58 (89) 59 (91) 0.512
History of Stroke 6 (9) 6 (9) 4 (6) 11 (17) 0.219
Hypertension 50 (77) 46 (71) 50 (77) 57 (88) 0.131
Male gender 16 (25) 53 (82) 58 (89) 65 (100) ,0.001
Waist Circumference (cm) 95.5 (80.5–105.8) 98.0 (84.0–108.0) 105.0 (92.0–118.0) 106.0 (92.0–118.0) 0.016
Abdominal aortic aneurysm 19 (29) 25 (38) 33 (51) 29 (45) 0.078
Intermittent claudication 40 (62) 32 (49) 27 (42) 29 (45) 0.110
AAA & IC 6 (9) 8 (12) 5 (8) 7 (11) 0.836
Medications
Aspirin 43 (66) 46 (71) 42 (65) 45 (69) 0.872
ACE inhibitor 21 (32) 31 (48) 26 (40) 29 (45) 0.307
Angiotensin receptor blocker 17 (26) 8 (12) 9 (14) 16 (25) 0.092
Beta-Blocker 25 (38) 29 (45) 18 (28) 24 (37) 0.251
Calcium channel blocker 22 (34) 16 (25) 22 (34) 24 (37) 0.469
Other anti-platelet 9 (14) 11 (17) 8 (12) 12 (18) 0.757
Statin 40 (62) 44 (68) 36 (55) 41 (63) 0.544
Warfarin 7 (11) 8 (12) 5 (8) 5 (8) 0.754
Cardiovascular Outcomes
Follow-up (years) 2.7 (1.0–4.6) 3.7 (1.3–5.5) 2.3 (1.0–4.0) 2.9 (1.6–4.8) 0.306
Myocardial infarction 9 (14) 8 (12) 1 (2) 8 (12) 0.072
Stroke 3 (5) 2 (3) 3 (5) 2 (3) 0.937
Death 16 (25) 11 (17) 14 (22) 15 (23) 0.735
$1 event* 22 (34) 17 (26) 16 (25) 21 (32) 0.586
Computed Tomography Imaging Morphology
Infra-renal aorta measurements
Maximum orthogonal w (mm) 23.3 (19.3–41.4) 29.8 (21.7–45.2) 43.5 (23.2–55.9) 35.7 (24.3–48.1) ,0.001
Total volume (cm3) 35.1 (22.1–90.6) 46.0 (27.9–107.0) 98.3 (32.0–153.1) 77.0 (35.5–115.6) ,0.001
Abdominal Fat Measurements
Total volume (cm3) 3895.8 (2145.8–5835.9) 3655.1 (2247.6–4938.4) 4047.5 (3238.2–5184.7) 4865.9 (3803.0–5641.0)
Visceral volume (cm3) 909.1 (380.0–1558.0) 1654.3 (927.7–2058.9) 2169.6 (1675.0–2809.1) 3112.3 (2562.2–3773.4) ,
Relative visceral adipose volume 0.258 (0.203–0.319) 0.432 (0.407–0.450) 0.524 (0.494–0.555) 0.639 (0.607–0.704)
Categorical variables are presented as numbers (%) and compared by Chi-square tests. Numerical variables are presented as median (inter-quartile range) and compared
by Kruskal-Wallis tests. AAA=Abdominal aortic aneurysm; IC = intermittent claudication; ACE =Angiotensin converting enzyme; w=Diameter.
*$1 event (stroke, myocardial infarction or death). Relative visceral adipose volume= visceral-to-total abdominal adipose volume ratio. Quartiles are stratified by relative
visceral adipose volume in ascending order. Body mass index and waist circumference data was missing for 10 and 99 patients respectively. The significance level is 0.05.
Italicised font denotes significance.
doi:10.1371/journal.pone.0082350.t001
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hypertension and smoking history. Results of the Cox analysis are
presented as hazard ratios (HR) and 95% confidence intervals
(95%-CI). Only the first event was used in the Cox analysis if more
than one event was recorded for the participant.
Results
Characteristics of patients at recruitment
From May 2003 to February 2012 260 participants were
recruited. All study participants resided in north Queensland,
mostly from Townsville and surrounding communities. Table 1
illustrated the presenting characteristics of the patients in relation
to the quartile of relative visceral adipose volume defined as Q1
(lowest relative visceral adipose volume) to Q4 (highest relative
visceral adipose volume). The study group comprised 106 (41%)
cases with AAA, 128 (49%) cases with lower limb athero-
thrombosis and 26 (10%) cases with both AAA and athero-
thrombosis. Median relative visceral adipose volumes in Q1, Q2,
Q3 and Q4 were 0.26 [inter-quartile range (IQR) 0.20 to 0.32],
Figure 1. Kaplan Meier analysis illustrating freedom from cardiovascular events in relation to relative visceral adipose volume
quartiles. There was no significant association between the incidence of non-fatal myocardial infarction, non-fatal stroke or death and visceral
adiposity. *Cardiovascular event incidence at 3 years (P=0.517).
doi:10.1371/journal.pone.0082350.g001
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0.43 (IQR 0.41 to 0.45), 0.52 (IQR 0.49 to 0.56) and 0.64 (IQR
0.61 to 0.70) respectively. At entry higher relative visceral adipose
volume was noted in patients who were male, had diabetes, had a
larger WC and had larger abdominal aortas (Table 1). All other
characteristics were similar between quartiles of relative visceral
adipose volume.
Kaplan Meier Analysis
Patients were followed for a median of 2.8 years (IQR 1.2 to 4.8)
from the initial CTA until the first event or loss to follow-up. A
total of 92 major CVEs were recorded in 76 patients. The major
CVEs included myocardial infarction (n= 26), stroke (n = 10) and
death (n = 56). Overall the combined incidence of myocardial
infarction, stroke or death was 15% at 3 years. Higher relative
visceral adipose volume was not associated with the cumulative
incidence of major CVEs (Figure 1). At 3 years the incidence of
major CVEs was 15%, 17%, 11% and 15% for patients with
relative visceral adipose volume in quartiles one, two, three and
four, respectively, at entry, P=0.517. The incidence of non-fatal
myocardial infarction and non-fatal stroke were also not associated
with relative visceral adipose volume quartiles (Figure S1 and
Figure S2). The relationship between visceral adiposity and the
combined incidence of myocardial infarction, stroke or death were
also analysed separately for the following sub-sets of patients with
no significant associations found: Patients with and without
diabetes (Figure S3 and Figure S4); patients with AAA (Figure
S5) and patients with lower limb athero-thrombosis but no AAA
(Figure S6).
Cox proportional hazard analysis
Relative visceral adipose volume was not associated with
combined major CVEs after adjustment for traditional risk factors
(Table 2). Older age (HR 2.98; 95%CI 1.76 to 5.04) and coronary
heart disease (HR 1.76; 95%CI 1.03 to 3.00) were associated with
the incidence of combined major CVEs. Separate analyses for
non-fatal myocardial infarction and stroke are illustrated in Table
S1 and Table S2. There was no consistent association of visceral
adipose volumes with non-fatal myocardial infarction although
patients in quartile three did appear to have a lower incidence of
events compared to those in quartile one (HR 0.094; 95% CI
0.010 to 0.892) (Table S1). No association was found between
traditional cardiovascular risk factors and non-fatal stroke
incidence (Table S2). All patients who had non-fatal stroke had
a smoking history and hence the data was multi-collinear. The
data was re-analysed to exclude those participants without a
smoking history but the results were similar (not shown). Relative
visceral adipose volume was not associated with non-fatal stroke
incidence (Table S2). Separate analyses of the following sub-sets of
patients did not find any association between relative visceral
adipose volume and combined CVEs after adjustment for
traditional risk factors: Patients with and without diabetes; patients
with AAA and patients with lower limb athero-thrombosis but no
AAA (Table S3, Table S4, Table S5 and Table S6).
Table 2. Independent determinants of cardiovascular events (myocardial infarction, stroke or death) in patients with PAD.
Prognostic Factor Sample Size (n=260) Cardiovascular Events (n =76) HR (95% C.I.) P Value
Relative visceral adipose volume
Quartile 1 65 22 1 (Ref.)
Quartile 2 65 17 1.111 (0.520–2.371) 0.786
Quartile 3 65 16 1.035 (0.449–2.387) 0.935
Quartile 4 65 21 1.228 (0.509–2.960) 0.647
Age
Below median 126 24 1 (Ref.)
Above Median 134 52 2.981 (1.762–5.044) ,0.001
Coronary Heart Disease
Absent 125 26 1 (Ref.)
Present 135 50 1.758 (1.032–2.995) 0.038
Diabetes
Absent 176 49 1 (Ref.)
Present 84 27 1.025 (0.620–1.697) 0.922
Gender
Female 68 26 1 (Ref.)
Male 192 50 1.858 (0.901–3.829) 0.093
Hypertension
Absent 57 14 1 (Ref.)
Present 203 62 0.899 (0.463–1.745) 0.753
Smoking History
Absent 34 7 1 (Ref.)
Present 226 69 2.020 (0.876–4.656) 0.099
HR= hazard ratio, CI = confidence interval, Ref. = reference. Relative visceral adipose volume= visceral-to-total abdominal adipose volume ratio. Quartiles are stratified by
relative visceral adipose volume in ascending order. The significance level is 0.05. Italicised font indicates significance.
doi:10.1371/journal.pone.0082350.t002
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Discussion
The main finding from this study was that relative abdominal
visceral adipose volume assessed from thresholded CTA was not
associated with major CVEs in patients with PAD. The incidence
of major CVEs in this study was similar to other comparative
studies such as Alberts and colleagues who reported a 3 year
incidence for major CVEs of 6% and 12% for asymptomatic and
symptomatic PAD cases respectively [4].
Eight studies have previously assessed the association of various
anthropometric measures with CVEs in PAD populations (Table 3)
[2], [5], [6], [17], [18], [26–28] however no previous studies
specifically assessed abdominal visceral adipose volume. Of the
eight identified studies, two studies reported a more powerful
association of WC with CVEs than body mass index (BMI) [2],
[17]. Results from the studies that assessed BMI were conflicting:
two studies reported less CVEs in obese subjects [5], [18]; one
study reported a negative association of overweight but not obesity
with CVEs [28], one study reported an inverse association of
BMI.20 kg/m2 with CVEs [6] and one study did not find a
significant association between BMI and CVEs [27]. One study
did not find a significant association between WHR and CVEs
[26]. Although only based on two studies, these results suggest that
WC may be a more consistent predictor of CVEs than BMI in
PAD patients [2], [17]. WC is a commonly used estimate of
visceral adipose although it does not directly measure visceral
adipose volume [29].
Two studies have previously assessed the association of visceral
adipose measured from thresholded CTAs with CVEs although
these were not in patients with PAD [30], [31]. Gabriella and
colleagues assessed a group of HIV positive patients and
Kamimura and colleagues assessed a group of patients with
chronic kidney disease [30], [31]. Both studies reported an
association between visceral adipose and cardiovascular death
[30], [31]. BMI was not associated with CVEs [30]. However
Kamimura and colleagues assessed visceral adiposity by area from
axial slices rather than volume as has been reported in this study
[31]. Volumetric assessment could be suggested as a more accurate
estimate of visceral adiposity. Both studies used 10 mm thick axial
slices for assessment [30], [31] compared to this study which used
3 mm axial slices to provide a more detailed abdominal
examination.
The findings in the current study differ from the findings of
previous studies which have reported an association between WC
and CVEs [2], [17] however our method directly assessed visceral
adipose volume rather than other surrogate anthropometric
measures which are more commonly used. We postulated that
visceral adipose may be an important contributor to CVEs in
patients with PAD. The majority of arteries including the
abdominal aorta are surrounded by peri-vascular adipose tissue
[14]. Visceral adipose has been shown to release pro-inflammatory
adipokines which may promote adverse CVEs [14], [32–34].
However our findings suggest that other modifiable risk factors may
play a more powerful role in promoting CVEs in PAD patients.
Several studies have reported an ‘obesity paradox’ in cohorts of
patients with chronic disease such as heart failure [5], [18], [35–
37]. Higher BMIs ($30.0 kg/m2) have been associated with lower
mortality; overweight (25.0 to 29.9) kg/m2 and obese cases had a
lower risk of death relative to healthy BMI (18.5 kg/m2 to 24.9)
kg/m2 controls [5], [18], [35–37]. Reid and colleagues reported
that at 1 year the incidence of major CVEs in PAD cases was
higher in the normal weight group (11.6%) compared to the
overweight (10.9%) and obese groups (9.3%) [5]. While the
underlying mechanisms of the ‘obesity paradox’ remain unclear
[5] it appears likely the contradictory factors like nutritional status,
muscle mass and association of other risk factors such as physical
activity maybe important [2], [17], [18]. The findings of the
current study suggest that complications of PAD maybe better
limited by lifestyle modification targeting smoking cessation and
increased physical activity [38] and medical therapies (ACE
inhibitors [39], beta-blockers, aspirins and statins) rather than
therapies focused on adipose distribution per se [40].
This study has a number of limitations. Firstly considering the
need to adjust for confounding variables the sample size in this
study was relatively small but in line with our sample size
calculation. Secondly, patients were from a mixed group with
either AAA, lower limb athero-thrombosis or both. CTA imaging
of a ‘healthy’ control group would not have been ethical or
appropriate. Characteristics of the included participants were
however similar considering they had similar risk factors. Thirdly
measurements of visceral adiposity were limited to the abdomen
and did not include visceral adiposity from other sites.
In conclusion this study suggests that relative visceral adipose
volume is not associated with major CVEs in patients with PAD.
These findings do not support interventions specifically targeting
visceral adipose as secondary preventative measures in patients
with PAD.
Supporting Information
Figure S1 Kaplan Meier analysis illustrating freedom
from myocardial infarction in relation to relative
visceral adipose volume quartiles. There was no significant
association between the incidence of myocardial infarction and
visceral adiposity. *Myocardial infarction event incidence at 3
years (P=0.072).
(TIF)
Figure S2 Kaplan Meier analysis illustrating freedom
from stroke in relation to relative visceral adipose
volume quartiles. There was no significant association between
the incidence of stroke and visceral adiposity. *Stroke incidence at
3 years (P=0.857).
(TIF)
Figure S3 Kaplan Meier analysis illustrating freedom
from cardiovascular events in relation to relative
visceral adipose volume quartiles in patients with
diabetes at entry. There was no significant association between
the incidence of non-fatal myocardial infarction, non-fatal stroke
or death and visceral adiposity. *Cardiovascular event incidence at
3 years (P=0.432).
(TIF)
Figure S4 Kaplan Meier analysis illustrating freedom
from cardiovascular events in relation to relative
visceral adipose volume quartiles in patients that did
not have diabetes at entry. There was no significant
association between the incidence of non-fatal myocardial
infarction, non-fatal stroke or death and visceral adiposity.
*Cardiovascular event incidence at 3 years (P=0.297).
(TIF)
Figure S5 Kaplan Meier analysis illustrating freedom
from cardiovascular events in relation to relative
visceral adipose volume quartiles in patients with AAA
at entry. There was no significant association between the
incidence of non-fatal myocardial infarction, non-fatal stroke or
death and visceral adiposity. *Cardiovascular event incidence at 3
years (P=0.093).
(TIF)
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Figure S6 Kaplan Meier analysis illustrating freedom
from cardiovascular events in relation to relative
visceral adipose volume quartiles in patients that did
not have an AAA at entry. There was no significant association
between the incidence of non-fatal myocardial infarction, non-
fatal stroke or death and visceral adiposity. *Cardiovascular event
incidence at 3 years (P=0.480).
(TIF)
Table S1 Independent determinants of non-fatal myocardial
infarction in patients with PAD.
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Table S2 Independent determinants of non-fatal stroke in
patients with PAD.
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Table S3 Independent determinants of cardiovascular events
(myocardial infarction, stroke, death) in patients with PAD and
diabetes mellitus.
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Table S4 Independent determinants of cardiovascular events
(myocardial infarction, stroke, death) in patients with PAD without
diabetes mellitus.
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Table S5 Independent determinants of cardiovascular events
(myocardial infarction, stroke, death) in patients with AAA.
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Table S6 Independent determinants of cardiovascular events
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AAA patients.
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